Annals Internal Medicine, Author Interviews, CDC, Hospital Acquired, Infections / 02.08.2019
Drug Resistant Candida auris Presents Urgent Threat
MedicalResearch.com Interview with:
[caption id="attachment_50527" align="alignleft" width="185"]
This image depicts a strain of Candida auris cultured in a petri dish at the Centers for Disease Control and Prevention
Credit: Shawn Lockhart[/caption] Snigdha Vallabhaneni, MD, MPH Centers for Disease Control and Prevention Atlanta, GA MedicalResearch.com: What is the background for this study? Response: We are concerned about the fungus Candida auris (or C. auris) because it causes serious infections, is often resistant to medications, and continues to spread at alarming rates in U.S. healthcare settings. Candida. auris primarily affects patients in who are hospitalized for a long time or are residents of nursing homes that take care of patients on ventilators. C. auris is still rare in the United States and most people are at low risk of getting infected. People who get C. auris or other Candida infections are often already sick from other medical conditions and often have invasive medical care, including ventilators for breathing support, feeding tubes, central venous catheters, and have received lots of antibiotics. Many patients infected and colonized with C. auris move frequently between post-acute care facilities and hospitals, which increases the risk of spreading C. auris between facilities.
This image depicts a strain of Candida auris cultured in a petri dish at the Centers for Disease Control and PreventionCredit: Shawn Lockhart[/caption] Snigdha Vallabhaneni, MD, MPH Centers for Disease Control and Prevention Atlanta, GA MedicalResearch.com: What is the background for this study? Response: We are concerned about the fungus Candida auris (or C. auris) because it causes serious infections, is often resistant to medications, and continues to spread at alarming rates in U.S. healthcare settings. Candida. auris primarily affects patients in who are hospitalized for a long time or are residents of nursing homes that take care of patients on ventilators. C. auris is still rare in the United States and most people are at low risk of getting infected. People who get C. auris or other Candida infections are often already sick from other medical conditions and often have invasive medical care, including ventilators for breathing support, feeding tubes, central venous catheters, and have received lots of antibiotics. Many patients infected and colonized with C. auris move frequently between post-acute care facilities and hospitals, which increases the risk of spreading C. auris between facilities.
Dr. Wee[/caption]
Christina C. Wee, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Director , Obesity Research Program Division of General Medicine
Beth Israel Deaconess Medical Center (BIDMC)
Associate Program Director, Internal Medicine Program, BIDMC
Deputy Editor of the Annals of Internal Medicine
MedicalResearch.com: What is the background for this study?
Response: New research is showing that for many people without diagnosed heart disease, the risk of bleeding may outweigh the benefits of taking a daily aspirin particularly in adults over 70 years of age. The American Heart Association and the American College of Cardiology recently updated their guidelines and now explicitly recommend against aspirin use among those over the age of 70 who do not have existing heart disease or stroke.
Our study found that in 2017, a quarter of adults aged 40 years or older without cardiovascular disease – approximately 29 million people – reported taking daily aspirin for prevention of heart disease. Of these, some 6.6. million people did so without a physician's recommendation.
Yingxi (Cimo) Chen, MD, MPH, PhD
Postdoctoral Fellow
Radiation Epidemiology Branch, DCEG, NCI, NIH
Rockville MD 20850
MedicalResearch.com: What is the background for this study?
Response: Death rates from drug overdose have more than doubled in the US in the 21st century. Similar increases in drug overdose deaths have been reported in other high-income countries but few studies have compared rates across countries.
Dr. Shlipak[/caption]
Michael G. Shlipak, MD, MPH
Scientific Director , Kidney Health Research Collaborative (

